Country |
Geographical area |
Ref. |
Year |
Age range |
Sample size |
Cannabis (%) |
Cocaine (%) (1) |
Amphetamines (%) (2) |
Ecstasy (%)(3) |
LSD (%) |
|---|---|---|---|---|---|---|---|---|---|---|
Belgium |
National |
5 |
2001 |
15-34 |
2758 |
5.9 |
|
0.6 |
|
|
Czech Republic |
National |
1 |
2002 |
18-34 |
1002 |
|
|
|
|
|
Denmark |
National |
3 |
2000 |
16-34 |
4141 |
5.6 |
0.6 |
0.9 |
0.4 |
0.1 |
Germany |
National |
6 |
2003 |
18-34 |
3775 |
7.6 |
0.7 |
1.1 |
0.7 |
0.2 |
Estonia |
National |
2 |
2003 |
|
646 |
3.3 |
0.0 |
0.8 |
0.9 |
0.0 |
Greece |
National (except Aegean and Ionian Islands) |
3 |
2004 |
15-34 |
2620 |
1.5 |
0.1 |
0.1 |
0.0 |
0.0 |
Spain |
National |
4 |
2001 |
15-34 |
6915 |
11.9 |
2.4 |
1.1 |
1.5 |
|
France |
Metropolitan France |
5 |
2002 |
15-34 |
724 |
|
|
|
|
|
Ireland |
National |
4 |
2002-03 |
15-34 |
|
4.4 |
0.7 |
0.3 |
0.6 |
0.0 |
Italy |
National |
2 |
2003 |
15-34 |
5231 |
8.6 |
1.2 |
0.2 |
0.2 |
0.3 |
Cyprus |
National |
1 (4) |
2003 |
15-34 |
580 |
12.8 |
1.0 |
|
2.4 |
|
Latvia |
National |
1 |
2003 |
15-34 |
|
3.7 |
0.1 |
1.1 |
0.6 |
0.6 |
Luxembourg |
National |
1 |
1998 |
15-34 |
|
5.6 |
0.3 |
|
0.0 |
0.0 |
Hungary |
National |
2 |
2003 |
18-34 |
2319 |
2.8 |
0.4 |
0.8 |
0.8 |
0.3 |
Netherlands |
National |
2 |
2001 |
15-34 |
6687 |
7.0 |
0.9 |
0.5 |
1.3 |
0.0 |
Malta |
National |
1 |
2001 |
|
|
|
|
|
|
|
Poland |
National |
1 |
2002 |
16-34 |
|
2.7 |
0.1 |
0.5 |
0.4 |
0.1 |
Portugal |
National |
1 |
2001 |
15-34 |
6406 |
4.4 |
0.3 |
0.1 |
0.4 |
0.1 |
Slovakia |
National |
1 |
2002 |
18-34 |
|
5.9 |
0.0 |
0.2 |
0.2 |
|
Finland |
National |
5 |
2002 |
15-34 |
1240 |
2.9 |
0.1 |
0.5 |
0.2 |
0.0 |
Sweden |
National |
5 |
2004 |
18-34 |
2985 |
1.6 |
|
|
|
|
United Kingdom |
Northern Ireland |
6 |
2002-03 |
15-34 |
|
5.4 |
0.2 |
0.4 |
1.1 |
0.0 |
United Kingdom |
England and Wales |
8 |
2003-04 |
16-34 |
8590 |
12.0 |
2.4 |
1.1 |
1.9 |
0.2 |
Norway |
National |
1 |
1999 |
15-34 |
794 |
4.5 |
0.1 |
0.4 |
0.6 |
|
Notes: (1) Cocaine any form. (2) For Belgium National 2001 and for Metropolitan France 1995: amphetamine+ecstasy. (3) For Spain: ecstasy and other designer drugs. (4) Results of this survey should be viewed with caution due to important discrepancies with previous surveys and school surveys results. A new survey with a bigger sample is being conducted in 2005. This table aims to present national surveys. Exceptionally some relevant regional surveys are presented. Some city surveys reported by countries were not included as they tend to produce higher prevalence estimates, which are not comparable with estimates for whole countries (or big regions with urban and rural areas). Athens was included as reference point for 1993 survey. In surveys with small sample sizes results should be interpreted with caution. Countries were asked to report results using, as far as possible, EMCDDA standard age groups (all adults: 15 to 64, young adults: 15 to 34). In countries where age ranges are more restrictive prevalence estimates may tend to be slightly higher. Some countries have recalculated their prevalence figures using the EMCDDA standard age groups. For methods and definitions on population surveys in general, see [Methods and definitions - Prevalence and patterns of drug use in the general population]. Sources: See [Table GPS-0] | ||||||||||